---
title: Modulation of PD‑L1 expression by standard therapy in head and neck cancer
  cell lines and exosomes
date: '2023-07-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37503786/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230728180744&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Although checkpoint inhibitors (CPI) have recently extended the treatment
  options and improved clinical response of advanced stage head and neck squamous
  cell carcinoma (HNSCC), treatment success remains unpredictable. Programmed cell
  death ligand‑1 (PD‑L1) is a key player in immunotherapy. Tumor cells, and exosomes
  derived therefrom, are carriers of PD‑L1 and efficiently suppress immune responses.
  The aim of the present study was to analyze the influence of established therapies
  on ...
disable_comments: true
---
Although checkpoint inhibitors (CPI) have recently extended the treatment options and improved clinical response of advanced stage head and neck squamous cell carcinoma (HNSCC), treatment success remains unpredictable. Programmed cell death ligand‑1 (PD‑L1) is a key player in immunotherapy. Tumor cells, and exosomes derived therefrom, are carriers of PD‑L1 and efficiently suppress immune responses. The aim of the present study was to analyze the influence of established therapies on ...